| Tüüp : |
Ajaleht |
| Interneti link : |
http://www.ijpc.com/Abstracts/Abstract.cfm?ABS=284 |
|
| Uurimisrühmad : |
Houston - M.D.Anderson Cancer Center |
| Autor : |
Zhang YP, Trissel LA, Fox JL. |
| Pealkiri : |
Naratriptan hydrochloride in extemporaneously compounded oral suspensions. |
| Publikatsioon : |
Int J Pharm Compound ; 4: 69-71. 2000 |
|
| Tõendite tase : |
|
| Füüsikaline stabiilsus : |
|
| Keemiline püsivus : |
|
| Muud meetodid : |
|
| Kommentaarid : |
|
Ingredientide nimekiri
 Naratriptan Hydrochloride
|
 |
 |
 |
 |
15 mg
Amerge® |
| OraPlus® / OraSweet® (1:1) |
>> 30 mL |
|
23°C |
 |
| 7 |
 |
|
|
|
|
|
15 mg
Amerge® |
| OraPlus® / OraSweet SF® (1:1) |
>> 30 mL |
|
23°C |
|
| 7 |
|
|
|
|
|
|
15 mg
Amerge® |
| OraPlus® / OraSweet® (1:1) |
>> 30 mL |
|
4°C |
|
| 90 |
|
|
|
|
|
|
15 mg
Amerge® |
| OraPlus® / OraSweet SF® (1:1) |
>> 30 mL |
|
4°C |
|
| 90 |
|
|
|
|
|
